Biodesix Inc (BDSX) — SEC Filings
Biodesix Inc (BDSX) — 29 SEC filings. Latest: 10-Q (Nov 3, 2025). Includes 12 8-K, 5 10-Q, 2 DEF 14A.
View Biodesix Inc on SEC EDGAR
Overview
Biodesix Inc (BDSX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 3, 2025: BIODESIX INC (BDSX) reported a net loss of $8.716 million for the three months ended September 30, 2025, an improvement from a net loss of $10.258 million in the same period of 2024. Revenues increased significantly to $21.768 million for Q3 2025, up from $18.151 million in Q3 2024, representing a 1
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 3 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Biodesix Inc is neutral.
Filing Type Overview
Biodesix Inc (BDSX) has filed 5 10-Q, 12 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 2 SC 13G, 1 S-1/A, 2 SC 13D/A, 1 S-1 with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of BDSX's 24 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $59.744M |
| Net Income | -$31.285M |
| EPS | -$1.722 |
| Debt-to-Equity | N/A |
| Cash Position | $16.604M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | $47.111M |
Key Executives
- Scott Hutton
- Lawrence T. Kennedy, Jr.
- Frank F. Rahmani
- Samir A. Gandhi
- Jack W. Schuler
- Jack W. Schuler Living Trust
Industry Context
BIODESIX operates in the diagnostics and biopharmaceutical services sector, focusing on diagnostic tests. The competitive landscape likely involves other companies developing similar technologies and seeking partnerships with biopharmaceutical firms for drug development and companion diagnostics. Key industry trends include the increasing demand for personalized medicine, advancements in molecular diagnostics, and the growing importance of strategic collaborations between diagnostic companies and drug developers.
Top Tags
financial-reporting (5) · corporate-governance (4) · financials (4) · Biotechnology (3) · regulatory-filing (3) · 10-Q (3) · amendment (3) · Biodesix (3) · Net Loss (2) · Cash Burn (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Q3 2025 Revenue | $21.768M | Increased 19.9% from Q3 2024 |
| Q3 2025 Net Loss | $8.716M | Improved from $10.258M loss in Q3 2024 |
| YTD 2025 Revenue | $59.744M | Increased 17.4% from YTD 2024 |
| YTD 2025 Net Loss | $31.285M | Improved from $34.680M loss in YTD 2024 |
| Cash & Cash Equivalents | $16.604M | As of September 30, 2025, down from $26.245M at Dec 31, 2024 |
| Cash Used in Operations | $24.049M | For the nine months ended September 30, 2025 |
| Q3 2025 Net Loss Per Share | $(1.16) | Improved from $(1.40) in Q3 2024 |
| Reverse Stock Split | 1-for-20 | Effective September 15, 2025 |
| Long-term notes payable | $47.111M | As of September 30, 2025, up from $36.408M at Dec 31, 2024 |
| Total Stockholders' (Deficit) Equity | $(1.722)M | As of September 30, 2025, down from $20.876M at Dec 31, 2024 |
| SEC File Number | 001-39659 | Identifies the company's SEC filing history. |
| IRS Employer Identification No. | 20-3986492 | Company's tax identification number. |
| Commission File Number | 001-39659 | SEC identifier for the company |
| Net Loss | $13.5M | Increased from $10.8M in Q2 2024, indicating widening losses. |
| Total Revenue | $8.9M | Decreased from $9.2M in Q2 2024, a 3.3% decline. |
Frequently Asked Questions
What are the latest SEC filings for Biodesix Inc (BDSX)?
Biodesix Inc has 29 recent SEC filings from Feb 2024 to Nov 2025, including 12 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BDSX filings?
Across 29 filings, the sentiment breakdown is: 3 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Biodesix Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Biodesix Inc (BDSX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Biodesix Inc?
Key financial highlights from Biodesix Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BDSX?
The investment thesis for BDSX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Biodesix Inc?
Key executives identified across Biodesix Inc's filings include Scott Hutton, Lawrence T. Kennedy, Jr., Frank F. Rahmani, Samir A. Gandhi, Jack W. Schuler and 1 others.
What are the main risk factors for Biodesix Inc stock?
Of BDSX's 24 assessed filings, 3 were flagged high-risk, 9 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Biodesix Inc?
Forward guidance and predictions for Biodesix Inc are extracted from SEC filings as they are enriched.